Non-radiographic Axial Spondyloarthritis
📧 Sign up to get email alerts when something new happens for Non-radiographic Axial Spondyloarthritis.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-07-21EMA Authorised: Gobivaz (golimumab) — Advanz Pharma Limited
Authorised status for Gobivaz (golimumab) by Advanz Pharma Limited for multiple inflammatory diseases, expanding label in Europe.
-
EMA approval · 2026-07-01EMA Authorised: Gotenfia (golimumab) — Stada Arzneimittel AG
European Medicines Agency authorised Gotenfia (golimumab) by Stada Arzneimittel AG for multiple inflammatory diseases including various form…
-
EMA approval · 2026-06-12EMA Authorised: Fubelv — Biosimilar Collaborations Ireland Limited
EMA has authorised Fubelv as a biosimilar, with indications across various inflammatory arthritis and psoriasis conditions.
-
EMA approval · 2026-02-25EMA Authorised: Gotenfia (golimumab) — Stada Arzneimittel AG
The EMA authorised Gotenfia (golimumab) by Stada Arzneimittel AG for multiple inflammatory diseases, including rheumatoid arthritis, juvenil…
-
EMA approval · 2025-11-20EMA Authorised: Gobivaz (golimumab) — Advanz Pharma Limited
The EMA authorised Gobivaz (golimumab) for multiple inflammatory diseases. Indications include rheumatoid arthritis, juvenile idiopathic art…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2023-11-20FDA Tentative Approval: TALTZ — Supplemental Application (Eli Lilly and Company)
The FDA issued tentative approval for a supplemental application for TALTZ (ixekizumab) by Eli Lilly, indicating the submission is approvabl…
-
FDA approval · 2023-07-24FDA Approved: COSENTYX — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for Cosentyx (secukinumab) submitted by Novartis Pharmaceuticals Corporation.
-
FDA approval · 2020-06-16FDA Approved: COSENTYX — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for Cosentyx (secukinumab) submitted by Novartis Pharmaceuticals Corporation.
-
FDA approval · 2011-09-07FDA Approved: CIMZIA — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for Cimzia (certolizumab pegol) submitted by UCB, Inc. This action approves the changes described in…